Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Critically ill patient dies after Pluristem claims stem cell treatment a 'success'

12 November 2012

By Dr Daniel Grimes

Appeared in BioNews 681

A biotechnology company has come under fire after reporting the success of its 'life-saving' stem cell based therapies ahead of a major stock sale, which occurred before investors became aware of news that a patient who had received its treatment had died.

Two out of the three patients referred to in the relevant company press releases have now died, although no link between the deaths and the treatment has been suggested. The patients, affected by bone marrow disease, cancer and leukaemia, had exhausted all other treatment options and were at risk of 'imminent death', the company has emphasised.

Pluristem Therapeutics, an Israel-based stem cell company, had seen its stocks rise dramatically between May and September this year on the back of announcements that three patient's lives had been saved by its experimental stem cell therapies. A doctor who treated one of the patients called it a 'medical miracle'.

On 19 September, Pluristem completed a shares sale that generated $34 million for research expenses. However, it made no mention that one week before the sale one of the three patients – a seven-year-old girl with a bone marrow disease – had died. Subsequently, in a press release Pluristem announced that a second patient had died, although it is not clear when the death occurred.

In a statement, Pluristem denied that it knew of the girl's death at the time of the sale and that it withheld information from investors. 'The company did not learn of this fact until after the financing was completed', it said. The statement related that Pluristem was not monitoring the patient after she left hospital and that she had returned to her home country of Romania. Furthermore, it said there was 'no connection between the [stem cell treatment administered] and the death of the patient'.

The company has stood by its earlier announcements. Zami Aberman, Pluristem's chief executive officer, told Bloomberg News that because 'we saw significant improvement in the blood count, we declared a successful treatment'. The patients received treatment under the compassionate use programme, which allows experimental therapies to be used when no other treatment options are available. Pluristem said that the extended survival of the two patients that have subsequently died 'exceeded longevity expectations'. It added that, 'the unfortunate deaths of the patients do not diminish these results'.

It is not been suggested that Pluristem has breached any laws by its announcements or subsequent stock sale. John Nester, a spokesperson for the US Securities and Exchange Commission (SEC) told Bloomberg that the law requires companies 'to disclose information that a reasonable investor would consider important when deciding whether to buy, sell or hold a security'. It is not presently clear whether the SEC is investigating.

Most companies do not report on the results of compassionate treatments because of fears of raising false hope on the basis of a small number of cases. Christopher Bravery, an independent regulatory consultant told Bloomberg that such cases are 'purely anecdotal' and bear little statistical significance.

Pluristem said in its statement: 'Compassionate use cases are entirely experimental and last resort efforts in desperate situations and obviously not predictive of ultimate success or failure. Further, adverse results from causes unrelated to the subject therapy are also irrelevant in the evaluation of that therapy'.

According to Globes, several investment bankers have praised Pluristem for its 'transparency', saying that the company was 'maintaining a wonderful relationship with the capital market'.

Others have questioned the pitch of the initial sale. 'Such press releases risk misleading investors by creating overly optimistic account of scientific research', said Dr Leigh Turner, an associate professor at the University of Minnesota Centre for Bioethics. 'More importantly, press releases describing miracles and life-saving cures are harmful because they give seriously ill individuals an unrealistic account of effectiveness of experimental stem cell interventions'.

Pluristem's stem cell product, PLX cell treatment, is not currently approved for human use but has been involved in clinical trials. In the USA, unapproved treatments may be used for seriously ill patients where there is no treatment available.

SOURCES & REFERENCES
Bloomberg | 08 November 2012
 
How to Succeed At Shaving Millions Off A Company's Market Cap or Lie Trying
Reuters | 09 November 2012
 
Pluristem Comments on Article Published on Bloomberg
Pluristem (press release) | 09 November 2012
 
Globes | 08 November 2012
 
Bloomberg | 09 November 2012
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

17 February 2014 - by Dr Barbara Kramarz 
A leukaemia patient in the UK, previously given up to 18 months to live, is now in remission after transplant of stem cells from two babies' umbilical cords.
25 March 2013 - by John Brinsley 
Early results of an experimental gene therapy against an aggressive form of leukaemia have been hailed by researchers as showing 'life saving potential'....

22 October 2012 - by Dr Anna Cauldwell 
Two former CEOs of US drug company Geron are bidding to revive its stem cell assets...
30 July 2012 - by Ruth Retassie 
A US federal court has ruled that a stem cell product is classified as a 'drug', falling under the jurisdiction of the Food and Drug Administration (FDA). The ruling allows the FDA to regulate stem cell therapy in the USA and could open clinics that offer stem cell treatments open to federal liability...
18 June 2012 - by Dr Lucy Freem 
A ten-year-old Swedish girl has become the first recipient of a donor vein treated with a patient's own stem cells...
19 March 2012 - by Dr Sophie Pryor 
A cardiologist in Bonita Springs, Florida, USA, has had his medical licence suspended after allegedly performing an illegal stem cell treatment on a patient who died during the procedure...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation